|
WO2020097106A1
|
|
Use of tivozanib to treat subjects with refractory cancer
|
|
EP3448420A1
|
|
Anti-notch3 antibody
|
|
WO2016115149A1
|
|
Neuropilin-1 as a serum based biomarker
|
|
WO2016049470A1
|
|
Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
|
|
EP3157952A1
|
|
Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
|
|
AU2015276800A1
|
|
Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator
|
|
WO2014172653A2
|
|
Anti-notch1 antibodies
|
|
EP3689370A1
|
|
Anti-gdf15 antibodies
|
|
US2016185852A1
|
|
Anti-Notch3 antibodies
|
|
WO2014089193A1
|
|
Anti-fgfr2 antibodies
|
|
WO2014089055A1
|
|
Tivozanib response prediction
|
|
WO2013192094A1
|
|
Reconstituted human liver tumor model
|
|
CN104093859A
|
|
Identification of multigene biomarkers
|
|
CN108753942A
|
|
Predict the response of tumour confrontation ERBB3 antibody
|
|
WO2012006341A2
|
|
Anti-ron antibodies
|
|
WO2012003472A1
|
|
Anti-notch1 antibodies
|
|
WO2011156617A2
|
|
Anti-egfr antibodies
|
|
KR20130065665A
|
|
Anti-fgfr2 antibodies
|
|
AR080873A1
|
|
ANTIBODIES AGAINST EPIDERMIC GROWTH FACTOR (ANTI-ERBB3 OR ANTI-HER3)
|
|
US2011118297A1
|
|
Tivozanib and temsirolimus in combination
|
